USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN'S LYMPHOMAS

摘要

THE PRESENT INVENTION IS DIRECTED TO THE USE AN TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER, ESPECIALLY OF CD20 EXPRESSING CANCERS IN COMBINATION WITH ONE ORE MORE CHEMOTHERAPEUTIC AGENTS SELECTED FROM THE GROUP CONSISTING OF CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE. FIG 4.